Reviews and feature articleToward precision medicine and health: Opportunities and challenges in allergic diseases
Section snippets
General principles of precision medicine and health
One piece of evidence indicating that a concept has become mainstream is when it is widely used to sell products directly to physicians and consumers. For years, various commercial enterprises have been offering to sell individuals an analysis of their “genomes” (these analyses typically are not based on sequencing the full genome but on analyzing thousands of single nucleotide polymorphisms in individual genes) to trace their ancestry or, initially at least, even to permit them to assess their
Allergic disorders: A unique opportunity for the development of precision medicine and precision health
In the asthma field several recent studies have provided data indicating that proper selection of patients based on their clinical characteristics, including certain readily measurable features of their disorder (these can be called, generically, biomarkers), can identify subsets of patients more likely to respond favorably to biologics that impair the functioning of pathways implicated in the development of airway pathology in such subjects (for a recent review, see Berry et al20). In such
Preventing disease development
There is strong evidence that hereditary factors contribute to the propensity to allergic diseases.44, 45, 46 Therefore an effective way to reduce the incidence of allergic diseases in your children would be to select your spouse carefully, avoiding candidates who have a strong family history of allergic disorders. Such approaches already are being taken, along with adoption, to avoid the transmission of severe hereditary disorders that are based on the deleterious effects of single affected
Avoidance
Although the scrupulous avoidance of offending allergens is a mainstay of the management of allergic disorders,71 as noted above, this approach can be personalized, at least in principle, by using appropriate testing to carefully establish which allergens must be avoided and by defining the threshold amounts of such allergens individual subjects can ingest without triggering clinical signs and symptoms. Because various factors can alter one's threshold for clinically reacting to an offending
Cure
Allergen-specific immunotherapy has shown considerable success in modifying underlying disease in certain settings, notably in the setting of allergic rhinitis,74, 75, 76 and a number of promising approaches for developing novel immunotherapy vaccines are under investigation.77 Although determining whether successfully treated patients are truly cured of their disease depends on how one defines cure, many patients can experience long-term relief of symptoms, and their state of clinical
Disease monitoring in allergic disorders
If one unmet need in clinical allergy/allergology is to identify approaches that can accurately predict responsiveness to SIT, another is to develop disease-monitoring tests that can assess the extent to which such SIT is working in patients undergoing treatment. In the case of food allergies, initial studies indicate that some patients treated with oral immunotherapy (OIT) can achieve sustained clinical nonreactivity to a maintenance dose of the offending allergen, whereas others do not.78, 79
Toward precision medicine and health in the field of allergy
Providing the best possible personalized care for patients with allergic diseases and helping those at risk to avoid such disorders will be ongoing long-term efforts. However, it is possible to think now about general approaches for achieving those goals and to consider some broad principles for practicing precision medicine in the field of allergy (Table I). Notably, each of the topics listed in Table I has its own set of challenges.
For example, there is much current interest in defining
Clinical implications and future directions
It is difficult to imagine a more promising and exciting time in the history of clinical allergy/allergology. There can be no doubt that we face a big challenge, in that the factors which have contributed to the striking increase in the prevalence of allergic diseases since the late 19th century are probably both diverse in their nature and complex in their interactions.88 The good news is that there has been a marked increase in the power of new scientific and bioinformatics tools that can be
References (88)
Prophylactic inoculation against hay fever
Lancet
(1911)- et al.
Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine
Lancet
(1911) Vaccination against hay fever: report of results during the first three years
Lancet
(1914)Allergic sensitization is a key risk factor for but not synonymous with allergic disease
J Allergy Clin Immunol
(2014)- et al.
Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergen-chip
Methods
(2014) - et al.
Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome
J Allergy Clin Immunol
(2011) Predicting asthma outcomes
J Allergy Clin Immunol
(2015)- et al.
Biomarkers in asthmatic patients: has their time come to direct treatment?
J Allergy Clin Immunol
(2016) - et al.
Antisense molecules: a new class of drugs
J Allergy Clin Immunol
(2016) - et al.
Phenotype of asthma related with high serum periostin levels
Allergol Int
(2015)
Recent developments regarding periostin in bronchial asthma
Allergol Int
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
Lancet
Il-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel il-4/il-13 antagonist
J Allergy Clin Immunol
No increase in the serum periostin level is detected in elementary school-age children with allergic diseases
Allergol Int
What is an “eosinophilic phenotype” of asthma?
J Allergy Clin Immunol
Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Lancet Respir Med
Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants
J Allergy Clin Immunol
Environmental protection from allergic diseases: from humans to mice and back
Curr Opin Immunol
Microbiome influences on allergy in mice and humans
Curr Opin Immunol
Is vitamin D deficiency to blame for the asthma epidemic?
J Allergy Clin Immunol
Role of viral respiratory infections in asthma and asthma exacerbations
Lancet
How much is too much? Threshold dose distributions for 5 food allergens
J Allergy Clin Immunol
Risk multipliers for severe food anaphylaxis
World Allergy Organ J
Asthma genetics and personalised medicine
Lancet Respir Med
Allergen immunotherapy
J Allergy Clin Immunol
Molecular and cellular mechanisms of food allergy and food tolerance
J Allergy Clin Immunol
Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children
J Allergy Clin Immunol
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
J Allergy Clin Immunol
The allergy epidemics: 1870-2010
J Allergy Clin Immunol
Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual
J Allergy Clin Immunol
Allergy testing: the role of recombinant allergens
Clin Chem Lab Med
Overview of component resolved diagnostics
Curr Allergy Asthma Rep
Utility of component-resolved diagnostics in food allergy
Curr Allergy Asthma Rep
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Eur Respir J
Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics
Am J Respir Crit Care Med
T-helper type 2-driven inflammation defines major subphenotypes of asthma
Am J Respir Crit Care Med
Identification of asthma clusters in two independent Korean adult asthma cohorts
Eur Respir J
Elevated expression of the NLRP3 inflammasome in neutrophilic asthma
Eur Respir J
Asthma and wheezing in the first six years of life. The Group Health Medical Associates
N Engl J Med
Gene-environment interactions in asthma: with apologies to William of Ockham
Proc Am Thorac Soc
Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Committee on a Framework for Developing a New Taxonomy of Disease [Prepublication]. National Research Council of the National Academies
Categorization of allergic disorders in the new World Health Organization international classification of diseases
Clin Transl Allergy
Seven questions for personalized medicine
JAMA
Direct-to-consumer genetic tests should come with a health warning
Pharm J
Cited by (66)
Multi-omics profiling approach in food allergy
2023, World Allergy Organization JournalThe upper-airway microbiome as a biomarker of asthma exacerbations despite inhaled corticosteroid treatment
2023, Journal of Allergy and Clinical ImmunologyDoes machine learning have a role in the prediction of asthma in children?
2022, Paediatric Respiratory ReviewsUltrasensitive electrochemiluminescence biosensor for the detection of carcinoembryonic antigen based on multiple amplification and a DNA walker
2021, Sensors and Actuators, B: ChemicalStrategic Outlook toward 2030: Japan's research for allergy and immunology – Secondary publication
2020, Allergology InternationalCitation Excerpt :During the process, it becomes necessary to standardize the diagnostic criteria and classification rule among different institutions to help advance research on pathophysiology and evaluate treatment efficacy. In addition, stratification of healthy individuals (selecting high-risk groups of “potential patients”) is also required to implement precision medicine11 and preemptive therapy, which will be described in the next section. Furthermore, the utilization of artificial intelligence (AI) in “big data” analysis and standardizing phenotypes in model organisms need to be promoted.
Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MD
Supported by National Institutes of Health grants U19AI104209 and R01AR067145 and the Department of Pathology of Stanford University.